Chronic Incretin Therapy Study
About this Study
Incretin action has not been studied to date in CF, and the role of these hormones (released by the small
intestine to promote secretion of insulin) in insulin secretion defects in CF is poorly defined. Studies
have shown that there is a possible link between decreased incretin action and impaired insulin secretion
in CFRD, as is seen in Type II diabetes.
Through this study we hope to better understand:
- The role that these hormones may play in the development of CFRD
- Whether incretin-based therapy can improve insulin secretion
This study will provide incretin-based therapy or placebo for a 6 month time period, in order to determine
whether this type of early intervention will improve insulin secretion in CF patients with varying levels
of glucose tolerance or early CFRD.